KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Research & Development (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Research & Development for 6 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 34.39% year-over-year to $10.9 million, compared with a TTM value of $32.5 million through Dec 2025, up 56.39%, and an annual FY2025 reading of $32.5 million, up 56.39% over the prior year.
  • Research & Development was $10.9 million for Q4 2025 at Aurinia Pharmaceuticals, up from $8.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $20.1 million in Q2 2022 and bottomed at $3.0 million in Q3 2024.
  • Average Research & Development over 5 years is $9.4 million, with a median of $9.9 million recorded in 2022.
  • The sharpest move saw Research & Development soared 228.95% in 2023, then plummeted 77.6% in 2024.
  • Year by year, Research & Development stood at $11.1 million in 2021, then decreased by 11.16% to $9.9 million in 2022, then rose by 3.63% to $10.2 million in 2023, then fell by 20.74% to $8.1 million in 2024, then soared by 34.39% to $10.9 million in 2025.
  • Business Quant data shows Research & Development for AUPH at $10.9 million in Q4 2025, $8.4 million in Q3 2025, and $7.4 million in Q2 2025.